Sergio Bracarda

Statistics

Publications

165

Citations

25.7K

H-Index

Active since

1988

Affiliations

Istituti di Ricovero e Cura a Carattere Scientifico(Current)

Azienda Ospedaliera S.Maria

Ospedale San Donato

Institut Gustave Roussy

Fondazione IRCCS Istituto Nazionale dei Tumori

Sergio Bracarda is an author at Istituti di Ricovero e Cura a Carattere Scientifico specializing in oncology, medicine, and metastatic disease treatment.

ORCID

Publications per year

1988–2025

165

Publications

165

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Robert J. Motzer, Nizar M. Tannir, Osvaldo Arén Frontera et al. · New England Journal of Medicine · 2018 · 4.6K citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Robert J. Motzer, Bernard Escudier, Stéphane Oudard et al. · The Lancet · 2008 · 3K citations

Medicine, Oncology, Pharmacology +11

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

Bernard Escudier, P. Koralewski, Alain Ravaud et al. · The Lancet · 2007 · 2.2K citations

Medicine, Oncology, Pharmacotherapy +16

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

Padmanee Sharma, Margitta Retz, Arlene O. Siefker‐Radtke et al. · The Lancet Oncology · 2017 · 1.7K citations

Medicine, Oncology, Urology +12

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

David F. McDermott, Mahrukh Huseni, Michael B. Atkins et al. · Nature Medicine · 2018 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +17

1–5 of 165